ORMP ORAMED PHARMACEUTICALS INC Investments/Divestments 8-K Filing 2025 - Royalty Agreement On February 28, 2025, Oramed Pharmaceuticals entered into agreements with Scilex for a $50 million convertible notes purchase and a royalty agreement for 4% of net sales from certain products, with Oramed entitled to 50% of the purchased receivables.Get access to all SEC 8-K filings of the ORAMED PHARMACEUTICALS INC